个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) plus letrozole (LET) vs placebo (PBO) plus LET in Asian postmenopausal women with estrogen receptore positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC)

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Xu, B.[1] * ; Hu, X.[2] ; Li, W.[3] ; Sun, T.[4] ; Shen, K.[5] ; Wang, S.[6] ; Cheng, Y.[7] ; Zhang, Q.[8] ; Cui, S.[9] ; Tong, Z.[10] ; Geng, C.[11] ; Huang, C-S.[12] ; Sriuranpong, V.[13] ; Ngan, K. C. R.[14] ; Chia, Y. H.[15] ; Wang, X.[16] ; Zhao, H.[17] ;
机构： [1]Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China [2]Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [3]Oncology, The First Hospital of Jilin University, Changchun, China [4]Oncology, Liaoning Province Cancer Hospital, Shenyang, Liaoning, China [5]Oncology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China [6]Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China [7]Oncology, Jilin Provincial Cancer Hospital, Changchun, China [8]Oncology, Harbin Medical University Cancer Hospital/Oncology Department, Harbin, China [9]Oncology, Henan Cancer Hospital, Zhengzhou, China [10]Breast Cancer, Tianjin Cancer Hospital, Tianjin, China [11]Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China [12]Surgery, National Taiwan University Hospital, Taipei, Taiwan [13]Oncology, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand [14]Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China [15]Oncology, Tan Tock Seng Hospital, Singapore [16]Oncology, Pfizer (China) R&D Co., Ltd., Shanghai, China [17]Statistics, Pfizer (China) R&D Co., Ltd., Shanghai, China
出处：
DOI： 10.1016/j.annonc.2021.08.511
ISSN：
基金：
Editorial support was provided by Anny Wu, PharmD, of ICON plc (North Wales, PA, USA) and was funded by Pfizer Inc.
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
推荐引用方式(GB/T 7714)：
Xu B.,Hu X.,Li W.,et al.PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) plus letrozole (LET) vs placebo (PBO) plus LET in Asian postmenopausal women with estrogen receptore positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC)[J].ANNALS OF ONCOLOGY.2021,32:S457-S457.doi:10.1016/j.annonc.2021.08.511.
APA：
Xu, B.,Hu, X.,Li, W.,Sun, T.,Shen, K....&Zhao, H..(2021).PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) plus letrozole (LET) vs placebo (PBO) plus LET in Asian postmenopausal women with estrogen receptore positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC).ANNALS OF ONCOLOGY,32,
MLA：
Xu, B.,et al."PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) plus letrozole (LET) vs placebo (PBO) plus LET in Asian postmenopausal women with estrogen receptore positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC)".ANNALS OF ONCOLOGY 32.(2021):S457-S457

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号